Abstract
Treatment of tuberculosis involves use of standardized weight-based doses of antibiotics, but there remains a substantial incidence of toxicities, inadequate treatment response, and relapse, in part due to variable drug levels achieved. Single nucleotide polymorphisms (SNPs) in the N-acetyltransferase-2 (NAT2) gene explain 88% of interindividual pharmacokinetic variability of isoniazid, one of the two most important antitubercular antibiotics. A major obstacle to implementing pharmacogenomic guided dosing is the lack of a point-of-care assay. We trained an acetylation genotype classification model from a global dataset of 5,738 genomes, which achieved 100% accuracy in out-of-sample prediction on unphased SNPs from 2,823 samples using 5 SNPs. On a clinical dataset of 49 patients with tuberculosis, we found that a 5 SNP assay accurately predicted acetylation ratios and isoniazid clearance. We then developed a cartridge-based molecular assay for the 5 SNPs on the GeneXpert platform, which enabled accurate classification of allele patterns directly from as little as 25 ul of whole blood. An automated pharmacogenomic assay on a platform widely used globally for tuberculosis diagnosis could enable improved dosing of isoniazid, averting toxicities and improving treatment outcomes.
Competing Interest Statement
JRA and RV are named co-inventors on a provisional patent (Application number 62/991,477) for a NAT2 pharmacogenomic assay
Clinical Trial
N/A
Funding Statement
FleXcartridges and technical support for their use were provided by Cepheid. This study was supported by the Institute for Immunity, Transplantation, and Infection and the Department of Medicine at Stanford University.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The clinical study was approved by the institutional review boards of the Stanford University School of Medicine and Federal University of Grande Dourados (IRB# 33005)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data supporting the findings of this manuscript are available in the Supplementary Information files or from the corresponding author upon request.
